Explore IBRX stock price, technical analysis, earnings, analyst targets, and buy/hold outlook for ImmunityBio. Is IBRX stock a buy? Get balanced insights now.
Introduction
ImmunityBio, Inc. (IBRX stock) develops cancer immunotherapies and vaccines. It focuses on treatments like Anktiva for bladder cancer.
Investors watch IBRX stock now due to rising biotech demand amid FDA approvals. Biotech stocks face headwinds from high interest rates but gain from innovation hype.
Latest Stock Price & Trend
IBRX stock closed at $9.78 on February 27, 2026, up 2.41% from $9.55.
The 52-week range spans $1.83 low to $12.43 high, with year-to-date gains strong from early 2026 lows around $2-3. One-month trends show volatility, climbing from $3-4 levels in January.
Over three months, IBRX stock surged from sub-$3 amid clinical news. Six-month trends reflect recovery from 2025 dips below $3. Year-to-date, it’s up sharply from $5+ starts, signaling bullish momentum.
This uptrend suggests investor confidence in pipeline progress, but volatility warns of risks for everyday investors.
Technical Analysis
Support levels sit near $8.83 recent low, where buyers stepped in. Resistance looms at $12.43 52-week high.
RSI at neutral ~52 indicates no overbought/oversold extreme; it measures momentum to spot reversals. MACD shows neutral trend, signaling crossovers for buy/sell shifts.
The 50-day moving average hovers below current price, while 200-day lags further— no golden cross (bullish 50 over 200) yet. Volume spiked to 30M shares, above 34M average, showing strong interest.
These point to potential upside if volume holds, but watch support breaks.
Analyst Ratings & Price Targets
Five analysts rate IBRX stock: 4 buys, 1 sell. Average price target $10.75, with high $24 and low $5—implying 10%+ upside from $9.78.
Recent views lean positive on pipeline. This sentiment hints at growth bets, but mixed calls urge caution for investors.
Insider Activity
Insider data shows limited recent buys or sells from filings. Management holds steady amid development focus.
No large transactions signal caution; steady activity implies quiet confidence.
Valuation Analysis
Trailing P/E stands negative at -25 due to losses. Forward P/E negative too, given EPS estimates -0.29 FY2026.
Price-to-sales high from low revenue $38M Q4 2025. Revenue grew YoY from $7.5M Q4 2024, EPS improved to -0.06 from -0.15. Free cash flow negative ~-$283M FY2026 est.
Debt details sparse, but cash burns high in biotech peers like early-stage firms. IBRX stock looks overvalued on metrics vs profitable biotechs, but growth potential justifies premium.
Recent Earnings & Catalysts
Q4 2025 revenue hit $38.3M, beating some views amid growth. EPS -0.06 topped -0.08 est.
Q3 revenue $32M missed $37.8M est, EPS -0.07 beat -0.10. Guidance points to FY2026 revenue ~$226M, EPS -0.29.
Catalysts include Anktiva approvals, pipeline advances in solid tumors. Earnings drove recent pops, but misses caused dips.
Bullish Case
Revenue growth from $14.7M FY to quarterly ramps shows commercialization.
Demand for immunotherapies rises with cancer needs. Tech edges in NK cells aid efficacy.
Operational ramps cut losses over time.
Bearish Case
Competition stiff from big pharma in immunotherapy.
Growth slows if trials fail; margins squeezed by R&D burn. Regulatory hurdles loom for approvals.
Economic slowdowns hit biotech funding.
Market Sentiment & Investor Psychology
Short interest unavailable, but high volume signals activity.
Institutions own big stakes: Vanguard 32M shares, BlackRock 25M—up recently. Optimistic sentiment from ownership trends.
Momentum bias strong post-earnings.
Short-Term Outlook
Technicals neutral with volume support.
Momentum could push to resistance if biotech rallies. Expect volatility around $9-10.
Medium to Long-Term Outlook
Strong pipeline in cancer vaccines bolsters model.
Biotech growth favors leaders; financials improving but cash burn key. Hold for long-term investors eyeing approvals; watch trial data.
FAQ Section
Is IBRX stock a buy right now?
Analysts lean buy with $10.75 target, but risks high—suits aggressive investors.
What is the price target for IBRX stock?
Average $10.75, high $24, low $5 from 5 analysts.
What are major risks for IBRX stock?
Trial failures, cash burn, competition in biotech.
IBRX earnings next?
Q1 2026 est EPS -0.09, revenue ~$45M.
IBRX forecast long-term?
Growth to positive EPS by 2028 if pipeline succeeds.
Suggestions
- Compare with Opendoor stock analysis
- See biotech sector forecast
- Read Anktiva approval impact
Final Balanced Conclusion
Watchlist IBRX stock. Growth potential offsets risks, but volatility suits patient investors.
Disclaimer: This article is for informational purposes only and not financial advice.